 This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicentre study of 52 weeks treatment duration. The primary objective is to evaluate the efficacyon endogenous insulin secretion, safety and tolerability of weekly albiglutide a glucagon-like peptide-1 receptor GLP-1R agonist versus placebo when added to insulin therapy in subjects with new-onset type 1 diabetes mellitus NOT1DM and residual insulin production.. Approximately 68 eligible subjects will be randomised in a 3:1 ratio such that 51 subjects receive albiglutide 30 milligram mg once weekly with increase to 50 mg once weekly at Week 6 if the 30-mg weekly dose is tolerated added-on to insulin therapy and 17 subjects receive placebo once weekly added-on to insulin therapy. The total duration of a subjects participation will be approximately 72 weeks up to 8 weeks of Screening, 52 weeks of treatment and 12 weeks of Post-treatment Follow-up 